Updated

Wall Street analysts project that shares of Axsome Therapeutics could rise as much as 35% over the next 12 months, prompting debate over whether the stock represents a straightforward buy at current levels. The bullish outlook centers on the biopharmaceutical company's drug pipeline and commercial execution. Investors are weighing the analyst optimism against typical biotech risks, including clinical and regulatory uncertainty, as they assess whether the projected upside is achievable within the stated timeframe.